Embed Size (px)
Citation preview
this issue Summit Presentation Schedule—AM P.1 Summit Presentation Schedule—PM P.2
Research Summit Keynote Speaker P.2 Research Highlight—Dynavision P.3
Micromedex in DynaMed Plus P.3 Policy Update—Conflicts of Interest P.4
New Studies P.4
I S SUE
42
March/April 2017
Who we are…
Genesis Health System Office of Research and Grants Administration is here to help you. If you need assistance please contact us.
Sarah Castro Research Support Liaison (563) 421-7957 [email protected]
Joy Lemmon Research Program Coordinator (563) 421-7956 [email protected]
Genesis Health System Research Promotion Fund To make a request to use the monies in the Research Promotion Fund, go to www.genesishealth.com/research and fill out the online application. You can also contact the Office of Research and Grants Administration for a copy of the application.
Once the Research Promotion Fund Committee receives a completed form, the committee does it's best to respond to applications within two weeks.
If you have questions about the Genesis Health System Research Promotion Fund, please direct them to Sarah Castro at [email protected].
Genesis Research Inquirer
GENESIS RESEARCH SUMMIT Friday, June 9, 2017
MORNING PRESENTATION SCHEDULE Genesis Heart Institute—Adler Education Center Auditorium
Time Speaker Topic
7:30—8:30 am Keynote Speaker: Dr. Enrique Leira
StrokeNet Research Network and Stroke Research at the University of Iowa
8:30—8:55 am Dr. Rodney Short Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
8:55—9:10 am BREAK
9:10—9:25 am Sarah Castro Research Program Update
9:25—9:50 am Blain Samuelson Orthopedic Research
9:50—10:15 am Amanda Wesson Catheter Removal Protocol
10:15—10:30 am BREAK
10:30—10:55 am Dr. David Mercer Oncology Research Highlights
10:55—11:20 am Sarah Castro and Yvonne Bonick
Can the Fitbit Wearable Activity Tracker Measure Caloric Expenditure in an Inpatient Ischemic Stroke Population?
11:20—11:45 am Dr. Nicolas Shammas Midwest Cardiovascular Research Foundation Research Highlights
11:45 am—1:00 pm LUNCH (on own)
AFTERNOON PRESENTATION SCHEDULE ON PAGE 2
Register online at www.genesishealth.com/cme
Genesis Research Inquirer March/April 2017
GENESIS RESEARCH SUMMIT AFTERNOON PRESENTATION SCHEDULE
All Genesis employees and community partners are welcome to join for all or part of the day. The Genesis Research Summit is a FREE event.
Research Summit Keynote Speaker— Enrique Leira, MD, MS Genesis is honored to present Enrique Leira, MD, MS as the keynote speaker for this year’s Research Summit on June 9. Dr. Leira is the Acting Director of the Comprehensive Stroke Center at the University of Iowa. He specializes in Cerebrovascular Diseases and Epidemiology. His research focus is acute stroke management, including evidence-based strategies to improve and accelerate stroke treatment in rural areas. Dr. Leira is the principal investigator for the University of Iowa Regional Coordinating Center (UIRCC) for StrokeNET, which Genesis participates in. StrokeNet is a research network created by the National Institutes of Health to efficiently conduct clinical trials to advance acute stroke treatment, stroke prevention and recovery and rehabilitation following a stroke. Dr. Leira will be offering the keynote address at the Research Summit on June 9th from 7:30 am - 8:30 am, focused on the innovative design of StrokeNET and its work, along with key research he has completed.
Time Speaker Topic
1:00—1:25 pm Chris Parker MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MEDFOCUS) and ICare
1:25—1:50 pm Dr. David Janseen and Dr. Jennifer Davison
Sugar Sense
1:50—2:15 pm Dr. Thang Luong, Dr. Brittany Davis, Dr. Michael Cloos and Dr. Habeeba Sirajuddin
Accountable Health Communities
2:15—2:30 pm BREAK
2:30—2:55 pm Jordan Brautigam Sleep Apnea Registry
2:55—3:20 pm Cheryl Johnson Does Gain Camp Influence Participants’ Decisions to Pursue a Career in Healthcare?
3:20—3:45 pm Lori Dryg, Cherie Blackwell, Kristen Mandle, Kathy Cary, Kami Holst, Emma Hendricks
Dynavision Normative Data for Reaction Time
3:45—4:10 pm Sara Bytnar Decreasing Readmission Rates in Congestive Heart Failure Patients
4:10—4:15 pm WRAP-UP
Did you know that drug information from Micromedex is accessible in DynaMed Plus? Micromedex is integrated into DynaMed Plus to make searching for drug information easier and simpler. As seen in the example below, type the name of the drug in DynaMed Plus and then from the left side choose Drug Interactions or Adverse Effects. As you scroll through the information on the right, you will come across a link that says, DRUGDEX Subscribers See additional details for (name of drug), click on the link. Please note that DRUGDEX links may also be found within the other topics listed on the left side.
The DRUGDEX Subscriber link will take you directly to the drug information in Micromedex:
If you have any questions, please feel free to contact the Medical Librarian: Karlene Campbell ([email protected] or 563-421-2287)
Genesis Research Inquirer March/April 2017
Research Highlight— Dynavision Normative Data for Reaction Time
Congratulations to the Dynavision Research Team: Lori Dryg, Cherie Blackwell, Kristen Mandle, Kathy Cary, Kami Holst, Emma Hendricks and Dr. Jon Lemke! After 3 years of enrollment and 300 participants, this team has completed enrollment in the Dynavision Normative Data for Reaction Time study! The purpose of this study was to collect normative data for visual reaction speed, physical response speed and motor response time for the Dynavision D2 Visuomotor Training System that is located at Genesis’s Devil’s Glen location. The Dynavision system is used to assess reaction times with patients who have experienced a brain injury or stroke. This study will allow Genesis Occupational Therapists to establish norms for visual reaction, physical response and motor response times to assist therapists in properly assessing and treating visual perceptual deficits. Visual perception is an important skill needed for activities of daily living such as reading, functional math, functional mobility and driving.
This study team will be presenting their study findings at the Research Summit on June 9! You don’t want to miss it!
Policy Update—Conflicts of Interest in Research
There was recently a change to the Genesis Conflicts of Interest in Research policy, which will reduce the number of trainings required for researchers that are NOT conducting research funded by the Public Health Service (e.g., National Institutes of Health, National Cancer Institute, Food and Drug Administration). The "Training" section of the Conflicts of Interest in Research policy was amended to apply only to individuals responsible for the design, conduct or reporting of a Public Health Service funded research study. This is consistent with the applicable law, 42 CFR Part 50, Subpart F, that identifies Conflict of Interest in Research training requirements for investigators. Investigators that do participate in Public Health Service funded research will need to complete Conflicts of Interest in Research Training once every four years, per federal regulation. The Genesis Research office will continue to notify eligible investigators of their training requirements and subsequent time line for completion. All individuals, regardless of funding, responsible for the design, conduct or reporting of a research study will still be required to complete the following items prior to participating in research at Genesis (as stated in the Conflicts of Interest in Research policy): 1. NIH Protecting Human Subjects in Research training, or equivalent (one-time) 2. Conflicts of Interest Disclosure (annually) The revised policy can be found on the Genesis Research website at www.genesishealth.com/research under the “Information for Researchers” tab. Please contact Sarah Castro at [email protected] or 563-421-7957 with any questions.
IRB Approved New Projects: March - April, 2017 4 New Studies Approved Ultrasound Guided Carpal Tunnel Release Principal Investigator: Dr. Tyson Cobb Rationale and Purpose: The purpose of this study is to evaluate a case series of patients undergoing the Micro-Invasive Carpal Tunnel Release procedure using the SX-One MicroKnifeTM under ultrasound guidance. DEFINE-PCI: Physiologic assessment of coronary stenosis following PCI Principal Investigator: Dr. Nicolas Shammas Rationale and Purpose: The purpose of this study is to determine the range of post-PCI iFR and the rate of significant residual ischemia defined as iFR <0.90 following operator-assessed angiographically successful PCI. Epidemiology of Summer Trauma in Scott County, IA Principal Investigator: Matthew Koch Rationale and Purpose: The objectives of this study are to: 1) identify high-risk areas in Scott County for specific mechanisms of injury, 1a) identify extreme outlying areas of trauma incidence and 2) determine what mechanisms of injury are most prevalent in Scott County. Impella RP System Principal Investigator: Dr. Jon Robken Rationale and Purpose: The Impella RP System is an FDA approved humanitarian device. The device provides percutaneous hemodynamic support for patients with right heart failure that need emergency support of the right heart.
Genesis Research Inquirer March/April 2017
